Leading the Way at Weill Cornell—daedalusfund


Scientific Advisory Committee

Arthur Bertelsen, PhD joined Bristol-Myers Squibb Research in April of 2010 as Vice President, Research Collaborations. In this role, Art has overall responsibility for the management of external research collaborations across all therapeutic areas. Art provides guidance and direction on the formation of new collaborations consistent with the strategic objectives of BMS Research and his group provides alliance management for external relationships until the programs transition to full development. This role includes externalization of BMS technology and early stage assets for collaborative development.  Art represents BMS as a member of the managing board of Allied-Bristol Life Sciences, LLC.  Prior to joining BMS, Art spent more than twelve years at Schering-Plough Research Institute, where he was responsible for all aspects of forming and managing external collaborations to discover therapeutics or integrate new technology into discovery operations. Prior to joining SPRI Art  served as SVP of Research for PharmaGenics, Inc., an oncology-focused biotech company that was acquired by Genzyme in 1997. Trained as a cellular and molecular biologist, before PharmaGenics, Art led research directed toward recombinant protein discovery and development, particularly focused on post-translational modification of peptide/protein therapeutics. 

Dr. Bertelsen holds an AB in biochemical sciences from Princeton University and received his MS and PhD degrees from the program for Cellular and Molecular Biology at New York University Medical Center.

Ben Bronstein, MD, has over 25 years of experience as a founder, executive, and investor in the life sciences industry.  He currently serves as Interim Chief Medical Officer of Cytrellis Biosystems, Inc., a clinical stage company developing a new class of aesthetic medical devices, and a Senior Advisor at HiFiBio, which is commercializing microfluidic technology for single cell molecular profiling and antibody discovery.  Previously, he was Chief Medical Officer at Stealth BioTherapeutics; a Visiting Scholar at the Wyss Institute of Biologically Inspired Engineering at Harvard University; Co-Founder and Senior Vice President at of Access BridgeGap Ventures; Chief Executive Officer at Neuron Systems, Inc. (now Aldeyra Therapeutics, Inc.); a co-founder and President and COO of Vidus Ocular, Inc. (acquired by OPKO Health); Vice President of R&D-Devices at OPKO Health; Chief Executive Officer at Spherics, Inc.; Managing Director at Zero Stage Capital Co.; and Founder, President, and Chief Executive Officer of Peptimmune, Inc. (acquired by Genzyme Corp.).  Dr. Bronstein started his entrepreneurial career at BioSurface Technology Inc. (acquired by Genzyme Corp.) where he served as a Vice President of Medical Affairs and Medical Director. 

Since June 2010, Dr. Bronstein has been a Director of Aldeyra Therapeutics, Inc. In addition, he serves as Executive Chairman of Cleveland Diagnostics, Inc. 

Dr. Bronstein began his professional career as a Staff Pathologist at the Massachusetts General Hospital and was on the faculty of Harvard Medical School. Dr. Bronstein holds an appointment as a Visiting Assistant Professor of Pathology and Laboratory Medicine at Weill Cornell Medicine.  He holds an MD degree, an MBA (with high honors), and an AB in Biology (magna cum laude), all from Boston University.

Bruce Leuchter, MD is a Managing Director at PJT Partners. where he provides capital markets and M&A advisory services to companies in the life sciences industry with a focus on the biotechnology sector. Dr. Leuchter is a physician by training and neuropsychiatrist by specialty. He completed residency training in Neurology and Psychiatry at NewYork-Presbyterian Hospital/Weill Cornell Medical Center and is a Diplomate of the American Board of Psychiatry and Neurology. Dr. Leuchter served as Director of Clinical Neuropsychiatry at Weill Cornell Medicine (formerly Weill Cornell Medical College) and maintains a faculty appointment of Clinical Assistant Professor of Psychiatry. Dr. Leuchter's financial services experience, prior to joining PJT Partners, includes roles in equity research and investment banking at Goldman Sachs and Credit Suisse, respectively. He joined Goldman Sachs in 2008 to spearhead a Global Investment Research initiative analyzing emerging biotechnology companies, and later joined Credit Suisse as an investment banker focused on the biotechnology sector. Given his background in neuroscience, he frequently advises companies developing technologies for diseases of the brain and nervous system. Dr. Leuchter co-founded Click Therapeutics, a digital medicine company which engineers, validates and commercializes digital therapeutics solutions to benefit people with unmet medical needs through cognitive and neurobehavioral modifications. He also serves as a Board member of the Global Lyme Alliance.

Richard Pasternak, MD retired from Merck in 2010, having served as Vice President, Clinical Research and Head, Cardiovascular Therapeutic Area (2004-2008), and Vice President, Head of Global Scientific Affairs and Scientific Leadership (2008-2010). Dr. Pasternak also served as a key Senior Executive in a communications role for Merck regarding critical issues related to scientific affairs, and was a policy liaison for medical and scientific issues. Prior to joining Merck, Dr. Pasternak was Director of Preventive Cardiology and Cardiac Rehabilitation at the Massachusetts General Hospital, Director of the Cardiology Practice Plan, and an Associate Professor of Medicine at Harvard Medical School, having been on the Harvard faculty since 1983. Dr. Pasternak is a Clinical Professor of Medicine, Adjunct Professor of Healthcare Policy and Research, and Adjunct Professor of Pharmacology at Weill Cornell Medicine.

Dr. Pasternak received his BA and MD from Yale University and completed his medical and cardiology training at the Massachusetts General Hospital. He is currently Chairman of the Board of Directors of Cerenis Therapeutics, and serves on the Boards of several other biotech companies.

Philip Reilly, MD, JD joined Third Rock Ventures in 2009 to discover, launch and build companies pursuing breakthrough treatments for rare genetic diseases. He is a highly respected clinical geneticist with an extensive track record of launching and building companies in the rare disease space. While at Third Rock, he has served as interim CMO of Voyager Therapeutics; Scientific Advisory Board member and interim CMO of Bluebird Bio; Co-founder and board member of Edimer; and board member of Lotus Tissue Repair. Prior to joining Third Rock, he was the chief executive officer and chairman of Interleukin Genetics, and before that, he was the executive director of the Eunice Kennedy Shriver Center for Mental Retardation. He served twice (2000 and 2003) as president of the American Society of Law, Medicine and Ethics.

Dr. Reilly is a founding fellow of the American College of Medical Genetics. He has authored or co-authored more than 100 articles in scholarly journals as well as several books about clinical genetics. In addition, he has held teaching positions at Tufts University School of Medicine and Harvard Medical School. 

Dr. Reilly served as a Trustee of Cornell University from 2006 – 2014 and is currently a member of the Board of Overseers of Weill Cornell Medicine. He received his BA from Cornell University and holds an MD from Yale University, a JD from Columbia University, is a member of the Massachusetts Bar, and is board certified in internal medicine and clinical genetics.

Andrew Schiff, MD joined Aisling Capital at its inception and currently serves as one of the Managing Partners. Prior to Aisling Capital, Dr. Schiff practiced internal medicine for six years at New-York Presbyterian Hospital, where he maintains his position as a Clinical Assistant Professor of Medicine. Dr. Schiff currently serves as a director of  ARMGO Pharma, PowerVision, Zavante (observer)  and ZELTIQ Aesthetics. Prior Board service includes Adams Respiratory Therapeutics, Agile Therapeutics ArgiNOx Pharmaceuticals, Barrier Therapeutics, Bioenvision, CardioKine, Cempra Pharmaceuticals, Miramar Labs, Myogen, SkinMedica, Sirion Therapeutics, TransEnterix and Quintiles (Board observer). He is a longtime supporter and Board member of the Visiting Nurse Service of New York.

 

Dr. Schiff received his M.D. from Cornell University Medical College, his M.B.A. from Columbia University, and his B.S. with honors in Neuroscience from Brown University.

Benny Soffer, MD joined Consonance in September of 2005 and currently serves as a Partner and co-Portfolio Manager. Prior to joining, Benny completed a residency in internal medicine at Yale, worked as a physician at Yale-New Haven Hospital and as a Clinical Instructor in Medicine at Yale University School of Medicine. In addition to his work as a physician, Benny served in a variety of managerial roles at Yale-New Haven Hospital, including as Medical Director of Clinical Process Improvement and as Interim Medical Director of Medical Information Systems. Benny is also a Clinical Assistant Professor of Medicine at Weill Cornell Medicine. Benny is a graduate of Williams College, where he received his BA in history, of Emory University, where he received his MD, and of Yale University, where he received his MBA.

 

Robert Speigel, MD, FACP, is the former Chief Medical Officer of Schering Plough and was involved in the filing of over 30 New Drug Applications and interacted with regulatory authorities in the U.S. and globally, serving on the executive committees overseeing all research projects and drug licensing activities. Since 2010 he has served on the Board of Directors and Scientific Advisory Committees of a number of public and private Biotech companies and organizations.  He also serves as an advisor to Warburg Pincus and the Israel Biotech Fund. He currently serves on the Board of Directors of Geron Corporation, Edge Therapeutics, and Sucampo Pharmaceuticals. He is Chairman of the Board of Neximmune and Vidac Pharmaceuticals.

Martin Vogelbaum currently serves as Corporate Vice President, Business Development at Celgene Corporation.  Prior to joining Celgene in 2015, Mr. Vogelbaum spent the past 22 years as life sciences venture capitalist most recently serving as a Partner at Rho Ventures since 2005 where he led investments in Gloucester Pharmaceuticals (acquired by Celgene), SARcode Biosciences (acquired by Shire), AqueSys (acquired by Allergan), Inotek Pharmaceuticals and Cara Therapeutics.  Mr. Vogelbaum received his AB in biology and history from Columbia University.

Andrew Weisenfeld has been an investment banker since 1989. Mr. Weisenfeld became a Partner at MTS Health Partners in January 2008, primarily responsible for the development of the life sciences and medical technology practices. Prior to joining, Mr. Weisenfeld was a Managing Director in Banc of America Securities’ Corporate and Investment Banking Healthcare Group. Mr. Weisenfeld co-led the firm’s life sciences practice, providing capital raising and strategic advisory services to both publicly traded and private companies. Prior to joining Bank of America in 2003, Mr. Weisenfeld was a Managing Director at JP Morgan and its predecessor company, Chase Securities, leading its Healthcare M&A business across all sectors of healthcare from middle of 1997 to beginning of 2003. Prior to joining Chase, Mr. Weisenfeld spent over five years in the M&A Group at Merrill Lynch. Throughout his career, Mr. Weisenfeld has worked on a wide range of advisory transactions including acquisitions, sale transactions and strategic relationships. Selected life sciences transactions include the sale of Colucid to Lilly, the sale of Celator to Jazz Pharmaceuticals, Acorda’s acquisitions of Civitas and Biotie, Otsuka’s acquisitions of Avanir and Neurovance, the sale of AesRx to Baxter, the merger of Trimeris and Synageva, Reata’s strategic partnership with Abbott Labs, Genzyme’s acquisition of Bioenvision, the sale of Corixa to GlaxoSmithKline, the sale of TKT to Shire, the sale of ALZA to J&J, the sale of BioChem Pharma to Shire, Lundbeck’s acquisition of Synaptic, and the sale of Gilead’s oncology assets to OSI. Mr. Weisenfeld has also been responsible for many life sciences financings, including such as the monetization of Immunogen’s Kadcyla’s royalty and acting as advisor in the Alder, Tracon and NuPathe IPOs. Mr. Weisenfeld is a board member of Public Health Solutions, a New York based not-for-profit. Mr. Weisenfeld is also an active alumnus of Cornell University. In addition to serving as a member of the scientific advisory committee of Weill Cornell Medicine’s Daedalus Fund for Innovation and the school’s Dean’s Council, he is also a member of the Cornell Dyson School’s Undergraduate Program Advisory Council. Mr. Weisenfeld holds an MBA from The Wharton School at the University of Pennsylvania and a BS from Cornell University.